Probiotics (living agents) & Clostridioides difficile infection (CDI) (recurrent)

There is no consensus on the efficacy of probiotics in preventing CDI, and more research is needed to establish effective protocols and identify which strains are most beneficial
Barbosa et al. 2023 Front Med (Lausanne) 10: 1219225

Probiotics: potentially useful for CDI prevention in association with antibiotics
Ortigão et al. 2020

A recent Cochrane review showed that co-administration of probiotics with antibiotics was associated with a lower risk for CDI, but current guidelines do not yet recommend the routine use of preventive probiotics
Goldenberg et al. 2017 Cochrane Database Syst Rev. 12: CD006095

There is insufficient evidence to recommend probiotic therapy as an adjunct to antibiotic therapy for C. difficile colitis. There is no evidence to support the use of probiotics alone in the treatment of C. difficile colitis
Pillai & Nelson 2008 Cochrane Database of Systematic Reviews (Issue 1) Art no.: CD004611

see also:
CP101 & Clostridioides difficile infection (CDI) (recurrent)
Microbial Ecosystem Therapeutics 2 (MET-2) & Clostridioides difficile infection (CDI) (recurrent)
Pathogens / Pathobionts / Pathogenic Bacteria & Probiotics (living agents)
RBX2660 & Clostridioides difficile infection (CDI) (recurrent)
RBX7455 & Clostridioides difficile infection (CDI) (recurrent)
Saccharomyces boulardii + Metronidazole & Clostridioides difficile infection (CDI) (recurrent)
Saccharomyces boulardii + Vancomycin & Clostridioides difficile infection (CDI) (recurrent)
SER-109 & Clostridioides difficile infection (CDI) (recurrent)
VE303 & Clostridioides difficile infection (CDI) (recurrent)